Connection

Co-Authors

This is a "connection" page, showing publications co-authored by STEVEN JAY FRANK and SEUNGTAEK CHOI.
Connection Strength

1.469
  1. Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer center. Clin Transl Radiat Oncol. 2024 Sep; 48:100822.
    View in: PubMed
    Score: 0.244
  2. A Novel Polymer-Encapsulated Multi-Imaging Modality Fiducial Marker with Positive Signal Contrast for Image-Guided Radiation Therapy. Cancers (Basel). 2024 Jan 31; 16(3).
    View in: PubMed
    Score: 0.236
  3. Proton therapy for the management of localized prostate cancer: Long-term clinical outcomes at a comprehensive cancer center. Radiother Oncol. 2023 Nov; 188:109854.
    View in: PubMed
    Score: 0.229
  4. Long-term tumor control after brachytherapy for base-of-prostate cancer. J Contemp Brachytherapy. 2011 Dec; 3(4):183-7.
    View in: PubMed
    Score: 0.102
  5. A volumetric trend analysis of the prostate and seminal vesicles during a course of intensity-modulated radiation therapy. Am J Clin Oncol. 2010 Apr; 33(2):173-5.
    View in: PubMed
    Score: 0.090
  6. Quantification of prostate and seminal vesicle interfraction variation during IMRT. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):813-20.
    View in: PubMed
    Score: 0.078
  7. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. J Clin Oncol. 2018 06 20; 36(18):1823-1830.
    View in: PubMed
    Score: 0.039
  8. Assessing the Quality of a Radiation Oncology Case-Based, Peer-Review Program in an Integrated Academic and Community Cancer Center Network. J Oncol Pract. 2016 Apr; 12(4):e476-86.
    View in: PubMed
    Score: 0.034
  9. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76.
    View in: PubMed
    Score: 0.033
  10. A single-field integrated boost treatment planning technique for spot scanning proton therapy. Radiat Oncol. 2014 Sep 11; 9:202.
    View in: PubMed
    Score: 0.031
  11. Proton therapy for seminoma: Case report describing the technique, efficacy, and advantages of proton-based therapy for seminoma. Pract Radiat Oncol. 2015 Mar-Apr; 5(2):135-40.
    View in: PubMed
    Score: 0.031
  12. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1074-84.
    View in: PubMed
    Score: 0.030
  13. Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Dec 01; 87(5):946-53.
    View in: PubMed
    Score: 0.029
  14. Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):346-51.
    View in: PubMed
    Score: 0.029
  15. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer. 2013 Sep 15; 119(18):3265-71.
    View in: PubMed
    Score: 0.028
  16. MR imaging of prostate cancer in radiation oncology: what radiologists need to know. Radiographics. 2013 May; 33(3):741-61.
    View in: PubMed
    Score: 0.028
  17. PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):e39-46.
    View in: PubMed
    Score: 0.027
  18. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys. 2013 Mar 01; 85(3):693-9.
    View in: PubMed
    Score: 0.027
  19. Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol. 2012 Sep; 23(9):2346-2352.
    View in: PubMed
    Score: 0.026
  20. Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease? Eur J Cancer. 2012 Jul; 48(11):1664-71.
    View in: PubMed
    Score: 0.026
  21. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J. 2012 Jan-Feb; 18(1):1-8.
    View in: PubMed
    Score: 0.026
  22. Dosimetric impact of fiducial markers in patients undergoing photon beam radiation therapy. Phys Med. 2012 Jul; 28(3):240-4.
    View in: PubMed
    Score: 0.025
  23. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1310-7.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.